Regeneron Pharmaceuticals Inc (REGN)
967.98
-10.23
(-1.05%)
USD |
NASDAQ |
May 16, 16:00
967.70
-0.28
(-0.03%)
After-Hours: 20:00
Regeneron Pharmaceuticals Research and Development Expense (Annual): 4.439B for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 4.439B |
| December 31, 2022 | 3.592B |
| December 31, 2021 | 2.860B |
| December 31, 2020 | 2.735B |
| December 31, 2019 | 2.45B |
| December 31, 2018 | 1.469B |
| December 31, 2017 | 2.075B |
| December 31, 2016 | 2.052B |
| December 31, 2015 | 1.621B |
| December 31, 2014 | 1.271B |
| December 31, 2013 | 859.95M |
| December 31, 2012 | 625.55M |
| December 31, 2011 | 529.51M |
| December 31, 2010 | 489.25M |
| December 31, 2009 | 398.76M |
| Date | Value |
|---|---|
| December 31, 2008 | 274.90M |
| December 31, 2007 | 201.61M |
| December 31, 2006 | 137.06M |
| December 31, 2005 | 155.58M |
| December 31, 2004 | 136.10M |
| December 31, 2003 | 136.02M |
| December 31, 2002 | 124.93M |
| December 31, 2001 | 91.54M |
| December 31, 2000 | 56.26M |
| December 31, 1999 | 44.90M |
| December 31, 1998 | 37.00M |
| December 31, 1997 | 27.80M |
| December 31, 1996 | 28.30M |
| December 31, 1995 | 23.30M |
| December 31, 1994 | 39.70M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
2.45B
Minimum
2019
4.439B
Maximum
2023
3.215B
Average
2.860B
Median
2021
Research and Development Expense (Annual) Benchmarks
| Vertex Pharmaceuticals Inc | 3.163B |
| Eli Lilly and Co | 9.313B |
| Amgen Inc | 4.784B |
| Gilead Sciences Inc | 5.718B |
| Moderna Inc | 4.845B |